FDA CBD Roundup

On May 31, 2019, the U.S. Food and Drug Administration (“FDA”) held a much-anticipated public hearing regarding “Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds.” Since that time, FDA has reiterated its existing regulatory and enforcement approach to products containing cannabidiol (“CBD”) while also evaluating other science-based policy approaches for CBD products.…